This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Granulomatosis with Polyangiitis (Wegener)베게너육아종증 (Wegener육아종증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M31.3 | Special Copayment Reduction: V135 (rare disease Special Copayment Reduction)
B. SynonymsWegener's granulomatosis | necrotizing respiratory granulomatosis
C. Adult onsetLikelihood of first onset in adulthood: high — the median age at onset is 40–65 years, and it is mainly diagnosed in adults. It also occurs in children but is rare. It is common for patients to visit otolaryngology with chronic upper airway symptoms (nosebleeds, nasal septal perforation) and only later be confirmed as having systemic vasculitis.
1. History1931: described by Klinger → 1936–1939: Wegener defined it in 3 cases → 1954: systematized by Godman and Churg → 1982: ANCA discovered → 1985: association with PR3-ANCA → 2012: renamed GPA at the CHCC.
2. CausesPR3-ANCA (c-ANCA) is the main pathogenic factor; environmental triggers (nasal colonization by Staphylococcus aureus, silica dust exposure); combined mechanism of autoimmunity + granuloma formation.
3. GeneticsHLA-DPB1*0401 associated with PR3-ANCA; association with SERPINA1 (α1-AT) deficiency variants. CTLA4 and PTPN22 polymorphisms. There is a genetic predisposition, but it is not a single-gene disease.
4. General epidemiologyAbout 2–12 new cases per million per year; middle age 40–65 years, predominantly White; similar in men and women. Seasonal variation (more onset in winter and spring) reported.
5. PathophysiologyPR3-ANCA → neutrophil hyperactivation → vascular endothelial injury → small-vessel necrotizing vasculitis + CD4+ Th1 → histiocytes/giant cells → granuloma formation.
6. SymptomsUpper airway (nosebleeds, saddle nose, sinusitis) + lungs (cough, hemoptysis, nodules, cavities) + kidneys (hematuria, proteinuria, renal failure) + systemic (fever, weight loss).
7. SignsSaddle nose (nasal septal perforation); PR3-ANCA positive (c-ANCA); nodules and cavities on lung CT; pauci-immune glomerulonephritis of the kidney; granulomatous vasculitis on upper airway biopsy.
8. ScreeningANCA panel with a combination of unexplained nasal symptoms, saddle nose, cavitating lung nodules and hematuria. Screening with nasal endoscopy + chest CT + urinalysis.
9. DiagnosisACR 1990 criteria (2 of 4 items) + PR3-ANCA + tissue biopsy (triad of granulomatous necrotizing vasculitis). Lung or nasal biopsy preferred.
10. TreatmentRemission induction: steroids + cyclophosphamide or rituximab. Remission maintenance: rituximab (preferred) or azathioprine or methotrexate. TMP-SMX: suppression of Staphylococcus aureus.
11. PrognosisAfter introduction of modern treatment (rituximab), 5-year survival is 75–85%; relapse 30–50%; renal failure and infection are the main causes of death. Achieving early remission is key to preserving renal function.
12. PreventionTMP-SMX (suppression of Staphylococcus aureus + PCP prophylaxis); prevention of relapse with rituximab maintenance; prevention of complications of immunosuppression; meningococcal and pneumococcal vaccines.
13. References10 major international journals and guidelines

1. History

The history of Wegener's granulomatosis begins in 1931, when the German pathologist Heinrich Klinger described a rare case with abnormal findings in the nasal cavity and kidneys. However, the disease was established as an independent clinical entity in 1936–1939, when the German pathologist Friedrich Wegener published three cases. Wegener described a new disease characterized by the triad of necrotizing granulomas of the nasal cavity and sinuses, necrotizing nodules of the lungs and glomerulonephritis, and proposed it as an independent disease.

In 1954, Jacob Godman and Jacob Churg systematized the pathological features of this disease, establishing the triad of necrotizing granulomas of the lungs and upper airway, glomerulonephritis, and systemic vasculitis. With this description, the name "Wegener's granulomatosis" became established.

The decisive pathogenetic turning point came in 1982, when Davies et al. in Australia first discovered antineutrophil cytoplasmic antibodies (ANCA), and in 1985, when van der Woude et al. in the Netherlands reported that PR3-ANCA (cytoplasmic ANCA, c-ANCA) is specifically positive in Wegener's granulomatosis. This discovery brought revolutionary change to the diagnosis of the disease and to research on its pathogenesis. The ACR classification criteria were established in 1990, and in the 1994 CHCC nomenclature it was first formally classified as a distinct vasculitis. In the revised 2012 CHCC nomenclature, following the rediscovery of the historical fact that Wegener, after whom the disease was named, had been a Nazi party member, the name "Wegener's granulomatosis" was officially changed to Granulomatosis with Polyangiitis (GPA). In Korea, the name Wegener's granulomatosis is still used in clinical practice, and the disease is managed under Special Copayment Reduction code V135.


2. Causes

The etiology of Wegener's granulomatosis (GPA) is understood as a complex interaction of autoimmune, infectious, and environmental factors, and ANCA (especially PR3-ANCA) is established as the key pathogenic factor.

Role of PR3-ANCA: PR3-ANCA (anti-proteinase 3 antibody) is positive in about 75–90% of classic GPA. PR3-ANCA binds to proteinase 3 (PR3) expressed on the neutrophil surface and activates neutrophils, and the activated neutrophils directly damage vascular endothelial cells. PR3 is stored in the primary granules of neutrophils and translocates to the cell surface when stimulated by proinflammatory cytokines (TNF-α, IL-8). ANCA bound to PR3 activates neutrophils via Fc receptors, causing degranulation, reactive oxygen species generation, and NET release. This hyperactivation of neutrophils damages the vessel wall and causes vasculitis, which is the core pathogenesis of GPA.

Nasal colonization with Staphylococcus aureus: The frequency of upper airway nasal colonization with Staphylococcus aureus is higher in GPA patients than in the general population. It has been hypothesized that S. aureus proteins (especially LAMP-2-like proteins) may trigger an autoimmune response through molecular mimicry with PR3. Clinical evidence that prophylactic TMP-SMX (trimethoprim-sulfamethoxazole) suppresses S. aureus colonization and reduces GPA relapse supports this association.

Environmental factors: There are reports that exposure to silica dust and work in certain occupations (quarrying, sandblasting) increase the risk of GPA and other ANCA-associated vasculitides. Smoking has no clear association with the risk of developing GPA.

Mechanism of granuloma formation: Granuloma formation, characteristic of GPA, results from interactions among CD4+ T cells (Th1-skewed), histiocytes, and multinucleated giant cells. PR3 is also thought to play a role in maintaining granulomatous lesions within tissues.


3. Genetics

Wegener's granulomatosis (GPA) is not caused by a single gene mutation but is a complex genetic disease arising from the interaction of multiple genetic susceptibility factors and environmental factors.

HLA association: HLA-DPB1*0401 is reported as the strongest genetic risk factor in PR3-ANCA-positive GPA patients. This allele is thought to efficiently present PR3 epitopes to CD4+ T cells, amplifying the autoimmune response. In MPO-ANCA-positive microscopic polyangiitis, the association with HLA-DQ is stronger, suggesting genetic differences between PR3-ANCA-associated GPA and MPO-ANCA-associated MPA.

SERPINA1 (α1-antitrypsin) gene variants: α1-antitrypsin (α1-AT) is the physiological inhibitor of PR3, and the SERPINA1 Z variant (E342K) associated with α1-AT deficiency is reported to increase susceptibility to GPA by about 3–5-fold. In α1-AT deficiency, PR3 activity is not inhibited, so tissue damage and immune responses may be amplified. This association forms the basis for research using α1-AT itself as a therapeutic target in GPA.

Immune-related genes: Studies have linked polymorphisms in CTLA4 (regulation of immune tolerance), PTPN22 (regulation of T-cell activation), and IL-10 to susceptibility to GPA and other autoimmune diseases. Variants in the PR3 and MPO genes themselves are also being studied, but clinical application is still limited.


4. General epidemiology

Wegener's granulomatosis (GPA) is the most common subtype of ANCA-associated vasculitis (AAV); its annual incidence is reported as about 2–12 per million population and its prevalence as about 24–157 per million.

Sex and age distribution: Men and women are affected almost equally, although some studies show a slight male predominance. Age of onset is most commonly 40–65 years, and it rarely occurs in children.

Racial and regional distribution: Incidence is highest in Europe (especially Northern Europe and Scandinavia). It is reported relatively rarely in Asia and Africa. An epidemiological feature of East Asia, including Korea, is that MPO-ANCA-associated microscopic polyangiitis is more common than GPA.

Epidemiology in Korea: The number of patients registered in Korea under M31.3 (Wegener's granulomatosis) is estimated at several hundred, and they are managed under Special Copayment Reduction code V135. Because MPO-ANCA-associated vasculitis tends to be more common than PR3-ANCA-associated vasculitis in East Asia, the proportion of MPO-ANCA positivity among Korean GPA patients may be higher than in Western populations.

Seasonality: Some studies report that GPA onset is more frequent in winter and spring, suggesting an association with upper respiratory infections (such as Staphylococcus aureus).

Systemic vs. localized form: GPA is broadly divided into a systemic form (involving the kidneys, lungs, and upper airway) and a localized form (limited to the upper airway and similar sites, without renal involvement). Localized GPA has a lower PR3-ANCA positivity rate and lower mortality, and some cases are ANCA-negative.


5. Pathophysiology

The pathophysiology of Wegener's granulomatosis (GPA) is a complex process in which two pathological mechanisms operate simultaneously: ANCA-mediated neutrophil activation and T-cell/histiocyte-mediated granuloma formation.

PR3-ANCA-mediated vasculitis: When proinflammatory cytokines such as TNF-α and IL-8 are released in response to infection (such as influenza) or environmental stimuli, PR3 in resting neutrophils translocates to the cell surface (priming). When circulating PR3-ANCA binds to this surface PR3, neutrophils become fully activated via Fcγ receptors (FcγRIIa and FcγRIIIb). Activated neutrophils ① generate large amounts of reactive oxygen species through the oxidative burst, ② release primary-granule proteases (PR3, elastase, cathepsin G) that degrade the extracellular matrix and vessel wall, and ③ form NETs (neutrophil extracellular traps) that further damage vascular endothelial cells. These processes cause necrotizing vasculitis of small and medium-sized vessels.

Mechanism of granuloma formation: Granulomas in GPA form in the upper airway, lungs, perirenal area, and elsewhere. When CD4+ T cells (Th1- and Th17-skewed) recognize autoantigens including PR3 and secrete INF-γ and IL-17, monocytes and histiocytes are activated, differentiate into multinucleated giant cells, and form granulomas. The center of the granuloma often contains an area of necrosis (geographic necrosis), surrounded by layers of histiocytes, giant cells, and lymphocytes.

Renal involvement (crescentic glomerulonephritis): ANCA-mediated neutrophil activation damages the glomerular microvasculature, causing crescentic glomerulonephritis (crescentic GN). Destruction of the glomerular basement membrane, fibrin deposition, and crescent formation in Bowman's space are seen. "Pauci-immune GN," with no or very scant immune deposits on immunofluorescence, is characteristic of ANCA-associated vasculitis.


6. Symptoms

Wegener's granulomatosis (GPA) is a systemic vasculitis characterized by three major sites of involvement—the upper airway, lungs, and kidneys—although various other organs can also be involved.

Upper airway and ENT symptoms: These are among the most common and characteristic symptoms. Nasal symptoms (chronic rhinorrhea, bloody discharge, nasal ulcers, nasal crusting) occur in most patients, and saddle nose deformity due to nasal septal perforation and destruction of the external nasal cartilage is the emblematic physical finding of GPA. Chronic sinusitis is common, and nasopharyngeal and oral ulcers also occur. Parotid swelling and ear complications (otitis media, conductive hearing loss) may also occur.

Pulmonary symptoms: Cough (dry or productive), hemoptysis, chest pain, and dyspnea occur. On chest CT, lung nodules—especially nodules with internal cavitation—are the characteristic imaging finding of GPA. Alveolar hemorrhage is rare but life-threatening. Tracheal and bronchial stenosis (subglottic stenosis) occurs distinctively in GPA and is an important cause of dyspnea.

Renal symptoms: ANCA-associated glomerulonephritis (crescentic, pauci-immune glomerulonephritis) causes hematuria (red blood cell casts), proteinuria, and rapidly progressive decline in renal function. In the absence of renal involvement, the disease is classified as localized GPA.

Other symptoms: Fever, weight loss, fatigue; ocular symptoms (orbital pseudotumor, scleritis, episcleritis, conjunctivitis, uveitis, decreased vision); skin (purpura, pyoderma gangrenosum); nervous system (peripheral neuropathy, cranial nerve involvement); arthralgia/arthritis; heart (pericarditis).


7. Signs

Physical signs and test findings of Wegener's granulomatosis (GPA) are central to diagnosis.

ENT signs: Nasal mucosal congestion, intranasal crusting, nasal septal perforation, and saddle nose deformity are characteristic. Anterior rhinoscopy directly shows nasal mucosal ulcers, crusting, and septal perforation. Subglottic stenosis presents as inspiratory stridor.

Serum ANCA: PR3-ANCA (c-ANCA) is positive in about 75–90% of classic GPA and less often in localized GPA. MPO-ANCA (p-ANCA) is also positive in some patients. ANCA titers correlate with disease activity and are used to predict treatment response and relapse.

Chest CT findings: Lung nodules (especially cavitary nodules), pulmonary infiltrates, and tracheobronchial wall thickening and stenosis are the characteristic imaging findings of GPA.

Renal findings: Red blood cell casts, hematuria, and proteinuria on urinalysis. Elevated serum creatinine. Renal biopsy shows pauci-immune crescentic GN.

Tissue biopsy: Nasal biopsy is the most accessible method, but the sensitivity of a single nasal biopsy is low at about 50–70%. Open lung biopsy or thoracoscopic lung biopsy has the highest diagnostic yield, and is most diagnostic when the triad of necrotizing granulomatous vasculitis (granuloma, vasculitis, necrosis) is identified.

1990 ACR criteria: GPA is classified when 2 or more of 4 items are met (nasal ulcers/bleeding; nodules, cavities, or fixed infiltrates on chest X-ray; urinary dysmorphic red blood cells or red blood cell casts ≥5/HPF; granulomatous inflammation on biopsy) (sensitivity 88%, specificity 92%).


8. Screening

There is no population-wide screening for Wegener's granulomatosis (GPA). However, targeted evaluation for early diagnosis is essential in patients presenting with a specific combination of clinical features.

Criteria for clinical suspicion: Evaluate for ANCA-associated vasculitis, including GPA, in the following situations: chronic bloody rhinorrhea with nasal septal perforation or saddle nose deformity; multiple lung nodules (especially cavitating) on chest CT; rapidly progressive glomerulonephritis (hematuria, red blood cell casts, declining renal function); orbital pseudotumor; unexplained simultaneous upper airway, pulmonary, and renal symptoms.

Initial screening tests: PR3-ANCA (c-ANCA), MPO-ANCA (p-ANCA) — combined ELISA and IIF; urinalysis (urine sediment: red blood cell casts, microscopic hematuria, proteinuria); serum creatinine; ESR, CRP; complete blood count; chest X-ray and/or chest CT (to identify lung nodules and cavities); nasal endoscopy (to assess the nasal mucosa); ophthalmologic examination (to identify ocular involvement).

Limitations of noninvasive screening: ANCA testing alone is insufficient for diagnosis. ANCA may be negative in localized GPA, and false-positive ANCA can occur in other diseases. Therefore, clinical findings and ANCA must be considered together, and tissue biopsy is often required for confirmation.


9. Diagnosis

Wegener's granulomatosis (GPA) is diagnosed by integrating clinical symptoms, ANCA testing, imaging findings, and tissue biopsy.

ANCA testing: PR3-ANCA positivity (c-ANCA pattern on indirect immunofluorescence, confirmed by ELISA) is the key test for classic GPA. ANCA titers are used not only for diagnosis but also for predicting disease activity and relapse. Even when ANCA is negative, biopsy confirmation is pursued if GPA is strongly suspected clinically.

Tissue biopsy: This is the gold standard for diagnosis. Biopsy sites include the lung (thoracoscopic lung biopsy, VATS), kidney, and nasal cavity. Lung biopsy is most diagnostic when the triad of ① necrotic granuloma, ② vasculitis, and ③ necrosis is identified. Nasal biopsy is easily accessible, but the sensitivity of a single biopsy is low, so repeat biopsies may be needed. Renal biopsy shows pauci-immune crescentic glomerulonephritis.

Imaging findings: Chest CT shows cavitating nodules, multiple lung nodules, pulmonary infiltrates, and tracheobronchial wall thickening. PET-CT is used to assess the distribution of active lesions. Sinus CT shows sinus mucosal thickening and bone erosion.

2022 ACR/EULAR classification criteria: The 2022 revised ACR/EULAR classification criteria score clinical findings, ANCA, and biopsy findings, improving the sensitivity and specificity of GPA classification. Points are assigned to nasal and sinus findings (nasal crusting, ulcers, polyps), ear findings, pulmonary findings, ANCA type, and biopsy findings for an overall assessment.


10. Treatment

Treatment of Wegener's granulomatosis (GPA) is divided into two phases, remission induction and remission maintenance, and the 2022 ACR/EULAR guidelines present the current standard.

Remission induction therapy: In severe GPA with life-threatening organ involvement (kidney, lung, brain, etc.), combined high-dose glucocorticoids and immunosuppressants are standard. Intravenous methylprednisolone pulse therapy (500–1,000 mg × 3 days) is followed by oral prednisolone (1 mg/kg/day) + rituximab (375 mg/m² once weekly × 4, or 1,000 mg × 2) or cyclophosphamide (IV 15 mg/kg every 2–3 weeks or oral 2 mg/kg/day). In the RAVE and RITUXVAS trials, rituximab showed remission induction efficacy equivalent to cyclophosphamide with lower toxicity, so rituximab is now recommended as the first choice for severe GPA. In mild or localized GPA, steroids + methotrexate (MTX) may be used.

Remission maintenance therapy: After remission is achieved, rituximab (500 mg every 6 months, for 2 years or longer) is preferentially recommended; azathioprine (2 mg/kg/day) or methotrexate (20–25 mg/week) may also be used. Steroids are gradually tapered during remission maintenance and discontinued if possible.

TMP-SMX (trimethoprim-sulfamethoxazole): Used to prevent relapse by suppressing nasal colonization with Staphylococcus aureus and to prevent PCP (Pneumocystis jirovecii pneumonia). PCP prophylaxis is mandatory during treatment with rituximab or cyclophosphamide.

Management of airway stenosis: Subglottic stenosis responds poorly to systemic immunosuppression and requires bronchoscopic local steroid injection, mechanical dilation, and in some cases surgical intervention.


11. Prognosis

Without treatment, the mean survival of Wegener's granulomatosis (GPA) was only about 5 months, but since the introduction of cyclophosphamide therapy the 5-year survival rate has improved to about 60–75%, and since the introduction of rituximab to about 75–85%.

Major prognostic factors: Impaired renal function at diagnosis (elevated creatinine) is the most important predictor of progression to renal failure. Time to treatment response, persistently positive ANCA titers, number of relapses, and cumulative organ damage (VDI, vasculitis damage index) affect long-term prognosis.

Relapse: GPA has the highest relapse rate among ANCA-associated vasculitides, with a 5-year relapse rate of about 30–50%. PR3-ANCA-positive GPA tends to relapse more than MPO-ANCA-positive MPA. A rise in ANCA titer may precede relapse, but changing treatment based on ANCA titer alone is not recommended.

Long-term complications: Chronic renal failure, hearing impairment (conductive or sensorineural), nasal septal perforation and saddle nose deformity, decreased vision, sequelae of airway stenosis, peripheral neuropathy, and complications of long-term steroid and cyclophosphamide therapy (infection, bladder cancer, lymphoma) are important contributors to long-term morbidity.

Causes of death: Renal failure and pulmonary hemorrhage due to active vasculitis are causes of early death, and opportunistic infections (pneumonia, sepsis) due to immunosuppressive therapy are an important cause of death. Managing infection risk during rituximab maintenance therapy is important.


12. Prevention

Primary prevention of Wegener's granulomatosis (GPA) (preventing its onset) is currently not possible. Prevention of relapse and of treatment complications is central to clinical management.

Suppression of Staphylococcus aureus colonization: There is randomized controlled trial evidence that TMP-SMX (trimethoprim-sulfamethoxazole, single strength daily or double strength 3 times/week) suppresses nasal colonization with Staphylococcus aureus and reduces GPA relapse by about 40%. It is also essential for PCP (Pneumocystis jirovecii pneumonia) prophylaxis during immunosuppression. Prophylactic TMP-SMX during steroid + rituximab or cyclophosphamide therapy is standard.

Rituximab maintenance therapy: After remission, rituximab maintenance therapy (500 mg every 6 months, for 2 years or longer) is the most effective way to prevent relapse. In the MAINRITSAN 1–3 trials, rituximab maintenance significantly reduced relapse rates compared with azathioprine.

Infection prevention: Influenza vaccine, pneumococcal vaccine (inactivated), meningococcal vaccine (given before rituximab therapy), and hepatitis B vaccine are recommended. Live vaccines are contraindicated during immunosuppression. If hypogammaglobulinemia develops due to B-cell depletion during rituximab therapy, intravenous immunoglobulin (IVIG) replacement is considered.

Prevention of osteoporosis and metabolic complications: During long-term steroid therapy, osteoporosis is prevented with calcium, vitamin D, and bisphosphonates. When cyclophosphamide is used, prevention of bladder toxicity (mesna, fluid intake) and surveillance for malignancy (bladder cancer) are needed.

Patient education: Educate patients to recognize signs of relapse (new nasal bleeding or crusting, recurrent hematuria, hemoptysis, neuropathic symptoms) and to contact their rheumatologist immediately. Ensure they know to consult their medical team before taking prescribed antibiotics and how to respond promptly to symptoms of infection.


13. References

  1. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum. 2011;63(4):863-864. DOI: 10.1002/art.30286.

  2. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. DOI: 10.1056/NEJMoa0909905. PMID: 20647199.

  3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.

  4. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. PMID: 2202311.

  5. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780. DOI: 10.1056/NEJMoa1404231.

  6. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. PMID: 12840090.

  7. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-427. DOI: 10.1056/NEJMoa1213277.

  8. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335(1):16-20. PMID: 8649497.

  9. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42(12):2666-2673.

  10. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790-2803. DOI: 10.1056/NEJMoa0802311.